Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMAZ / SHINE-ON long-term extension study of mirikizumab in pediatric ulcerative colitis and Crohn's disease
2023-506239-14-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 3, open-label trial of mirikizumab in autoimmune colitis, Crohn's disease and inflammatory bowel disease (IBD) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Percentage of participants with ulcerative colitis in modified Mayo Score clinical remission and Percentage of participants with Crohn's disease in Pediatric Crohn's Disease Activity Index clinical remission. Planned start Dec 2022; status: authorised.
02
Drugs
mirikizumab
03
Conditions
autoimmune colitisCrohn's diseaseinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on 2023-506239-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506239-14-00.